CHEK2 and neoplasm: Both the ATM and CHEK2 genes showed significantly higher mutation rates in patients with non‐TNBC versus patients with a TNBC tumor phenotype (ATM: 1.7% vs. 0.4%; P = .026; CHEK2: 3.3% vs. 0.8%, P = .002; Table 5).